Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ: MRNA )

35.01 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,277
Open 35.01
Bid (Size) 34.50 (2)
Ask (Size) 34.65 (3)
Prev. Close 35.01
Today's Range 35.01 - 35.01
52wk Range 29.25 - 170.47
Shares Outstanding 386,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Reasons MRNA is Risky and 1 Stock to Buy Instead
Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per share. This was partly due to its softer quarterly results and might have... 
Via StockStory
Exposures COVID-19
Top S&P500 movers in Tuesday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill

Performance

YTD
-16.64%
-16.64%
1 Month
+9.85%
+9.85%
3 Month
-18.32%
-18.32%
6 Month
-55.97%
-55.97%
1 Year
-68.30%
-68.30%

More News

Read More
What's going on in today's session: S&P500 movers
Via Chartmill
Gapping S&P500 stocks in Tuesday's session
Via Chartmill
Moderna Unusual Options Activity
Via Benzinga
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
Via ACCESS Newswire
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Via MarketBeat
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Where Will Vertex Pharmaceuticals Be in 10 Years?
Via The Motley Fool
BioNTech Surpasses Q4 Revenue Estimates
Via The Motley Fool
Okta, Moderna and MicroStrategy Are Among Top 10 Large-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio?
Via Benzinga
Stay informed with the top movers within the S&P500 index on Friday.
Via Chartmill
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
FDA Nominee Marty Makary Faces The Senate. Will He Toe The RFK Jr. Line?
Via Investor's Business Daily
Exposures Product Safety
What's going on in today's pre-market session: S&P500 movers
Via Chartmill
Why Moderna Stock Zoomed Nearly 16% Higher on Wednesday
Via The Motley Fool
Exploring the top movers within the S&P500 index during today's session.
Via Chartmill
Discover which S&P500 stocks are making waves on Wednesday.
Via Chartmill
Wednesday's pre-market session: top gainers and losers in the S&P500 index
Via Chartmill
Coatue's Philippe Laffont Just Bought Shares of This Beaten-Down Growth Stock That Wall Street Predicts Will Soar 80%
Via The Motley Fool
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Healthcare Stock to Own for Decades and 2 to Ignore
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Via The Motley Fool
Moderna Stock Heads For Weekly Loss As Retail Caution Prevails: Wealth Advisor Tells Why She's Staying On The Sidelines
Via Stocktwits
Topics Government
Exposures Political
Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds
Via Investor's Business Daily
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.